The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment

The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment

Abstract Recent data suggest a suboptimal antibody response to COVID-19 vaccination in patients with hematological malignancies. Neutralizing antibodies (NAbs) against SARS-CoV-2 were evaluated in 276 patients with plasma cell neoplasms after vaccination with either the BNT162b2 or the AZD1222 vacci...

Full description

Bibliographic Details
Main Authors: Evangelos Terpos, Maria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, Alexandros Briasoulis, Sentiljana Gumeni, Panagiotis Malandrakis, Despina Fotiou, Eleni-Dimitra Papanagnou, Magdalini Migkou, Foteini Theodorakakou, Maria Roussou, Evangelos Eleutherakis-Papaiakovou, Nikolaos Kanellias, Ioannis P. Trougakos, Efstathios Kastritis, Meletios A. Dimopoulos
Format: Article
Language:English
Published: Nature Publishing Group 2021-08-01
Series:Blood Cancer Journal
Online Access:https://doi.org/10.1038/s41408-021-00530-3

Internet

https://doi.org/10.1038/s41408-021-00530-3

Similar Items